This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Panakes Partners | |
|---|---|
| Name | Panakes Partners |
| Type | Private |
| Industry | Venture capital |
| Founded | 2012 |
| Headquarters | Milan, Italy |
| Key people | Davide Rigo, Fabrizio Grillo |
| Products | Early-stage investment, healthcare venture capital |
| Assets | €500M+ |
Panakes Partners is an Italian venture capital firm specializing in healthcare and life sciences investments. Founded in 2012 and headquartered in Milan, it focuses on financing early-stage biotechnology, pharmaceutical, medical devices, and digital health companies across Europe. The firm is active in sourcing, mentoring, and scaling startups, leveraging networks in academic research, hospital systems, and corporate partners.
Panakes Partners was established in 2012 amid a surge of European venture activity influenced by institutions such as European Investment Fund, European Commission initiatives, and national programs in Italy. Early milestones include seed investments aligned with translational research from University of Milan, Istituto Europeo di Oncologia, and collaborations with clinical centers like San Raffaele Hospital. The firm expanded its team during the 2010s alongside contemporaries such as Index Ventures, Sofinnova Partners, and Accel Partners and benefited from shifts in financing seen after the 2008 financial crisis. Panakes participated in cross-border syndicates with firms including Siena Biotech, Life Science Partners, and corporate venture arms such as Novartis Venture Fund and Roche Venture Fund.
Panakes concentrates on early-stage ventures in biotechnology, pharmaceuticals, medical devices, and digital health with a preference for companies emerging from translational research at institutions like Humanitas Research Hospital and European Molecular Biology Laboratory. Its strategy leverages academic spinouts tied to University of Oxford, Imperial College London, and École Polytechnique Fédérale de Lausanne as well as clinical validation pathways at centers such as Karolinska Institutet. The firm pursues active board participation, technical due diligence informed by collaborations with Milan Polytechnic and Karolinska University Hospital, and exit planning involving strategic acquirers like Johnson & Johnson, Pfizer, and AstraZeneca. Panakes engages co-investors including Seventure Partners, LSP (Life Sciences Partners), Novartis, and Pfizer Ventures to syndicate rounds and access licensing channels exemplified by deals with Takeda and Sanofi.
Panakes' portfolio includes companies spanning therapeutics, diagnostics, and medtech. Notable investments have been in firms developing novel oncology therapeutics, precision diagnostics, and digital therapeutics originating from research at European Institute of Oncology, Milan Cancer Center, and Max Planck Society labs. The firm has co-led rounds with Index Ventures, Sofinnova Ventures, and Lundbeckfond Ventures and supported exits to pharmaceutical companies such as Bristol-Myers Squibb and Eli Lilly and Company. Its portfolio companies have pursued regulatory pathways with agencies like the European Medicines Agency and the U.S. Food and Drug Administration, and have presented data at conferences including American Society of Clinical Oncology, European Society for Medical Oncology, and BIO International Convention.
Panakes' leadership team comprises partners with backgrounds in venture capital, scientific research, and pharmaceutical development. Senior figures have prior affiliations with institutions like Stanford University, Harvard Medical School, University College London, and industry groups such as GlaxoSmithKline and Roche. The firm maintains investment committees and scientific advisory boards including experts from European Molecular Biology Laboratory, Karolinska Institutet, and Imperial College London. Operational functions coordinate with legal advisors experienced with European Patent Office filings and with corporate development professionals formerly at Pfizer and Novartis.
Panakes has raised multiple funds targeting early-stage life sciences investing, attracting limited partners including pension funds, family offices, and corporate investors; notable institutional LPs have included national development entities analogous to Cassa Depositi e Prestiti and pan-European investors similar to European Investment Fund. Fund vintages have ranged across the 2010s and early 2020s, with assets under management reported in the hundreds of millions of euros. Portfolio exits and follow-on financings have involved public listings on exchanges such as Euronext and NASDAQ as well as trade sales to multinational pharmaceutical companies like Novartis and GlaxoSmithKline.
Panakes is recognized within European life sciences venture networks and has been cited in industry coverage alongside firms like Sofinnova Partners, LSP, and Index Ventures. Its portfolio companies have won grants and awards from organizations including Horizon 2020, Innovative Medicines Initiative, and national science foundations linked to Italian Ministry of Health programs. Panakes partners and portfolio CEOs have spoken at industry forums such as BioEurope, JP Morgan Healthcare Conference, and Hello Tomorrow and participate in collaborative initiatives with academic translational centers and hospital networks across Italy, France, and Germany.
Category:Venture capital firms Category:Healthcare companies of Italy